Pancreatic cancer: Diagnosis and management

American Family Physician

Volumn 73, Issue 3, 2006, Pages 485-492

  Freelove, Robert ^a,b   Walling, Anne D ^b  

^a Smoky Hill Family Medicine Residency Program   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DRONABINOL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MEGESTROL; MEGESTROL ACETATE; OPIATE; PANCREAS ENZYME; PANCRELIPASE;

ABDOMINAL DISCOMFORT; ARTICLE; BACKACHE; BILE DUCT; BLOOD VESSEL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CHOLEDOCHOJEJUNOSTOMY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIET THERAPY; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME REPLACEMENT; EPIGASTRIC PAIN; FAMILIAL CANCER; FAMILIAL DISEASE; GASTROJEJUNOSTOMY; HUMAN; MALABSORPTION; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITION; OBESITY; OBSTRUCTIVE JAUNDICE; PANCREAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS EXOCRINE INSUFFICIENCY; PANCREATICODUODENECTOMY; PANCREATITIS; PHYSICAL EXAMINATION; PYLORUS; RISK FACTOR; SMOKING; STENT; SUPPLEMENTATION; SURVIVAL RATE; TERMINAL CARE; TISSUE PRESERVATION; WEIGHT REDUCTION;

CHEMOTHERAPY, ADJUVANT; DIAGNOSTIC IMAGING; HUMANS; NEOPLASM STAGING; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PHYSICAL EXAMINATION; RADIOTHERAPY, ADJUVANT; TUMOR MARKERS, BIOLOGICAL;

EID: 32244433703     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Fuchs CS, Colditz GA, Stampfer MJ, Giovannucci EL, Hunter DJ, Rimm EB, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996;156:2255-60.
3. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995;273:1605-9.
4. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001;286:921-9.
5. Olsen GW, Mandel JS, Gibson RW, Wattenberg LW, Schuman LM. A case-control study of pancreatic cancer and cigarettes, alcohol, coffee, and diet. Am J Public Health 1989;79:1016-9.
6. Great Britain Department of Health. Nutritional aspects of the development of cancer: report of the Working Group on Diet and Cancer of the Committee on Medical Aspects of Food and Nutrition Policy. London: Stationary Office, 1998.
7. Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002;94:1168-71.
8. Tersmette AC, Petersen GM, Offerhaus GJ, Falatko FC, Brune KA, Goggins M, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7:738-44.
9. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997;89:442-6.
10. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54.
11. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE. Molecular pathology of pancreatic cancer. Cancer J 2001;7:251-8.
12. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
13. DiMagno EP. Cancer of the pancreas and biliary tract. In: Winawer SJ, ed. Management of gastrointestinal diseases. New York: Gower Medical Publishing, 1992:28.1-28.37.
14. Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer 1985;56:397-402.
15. McGee SR. Palpation and percussion of the abdomen. In: Evidence-based physical diagnosis. Philadelphia: Saunders, 2001:601-4.
16. Malesci A, Montorsi M, Mariani A, Santambrogio R, Bonato C, Bissi O, et al. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas 1992;7:497-502.
17. Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997;4:551-6.
18. Louhimo J, Alfthan H, Stenman UH, Haglund C. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 2004;66:126-31.
19. U.S. Preventive Services Task Force. Screening for pancreatic cancer: recommendation statement. Rockville, Md.: Agency for Healthcare Research and Quality. Accessed online September 28, 2005, at: http://www.ahrq.gov/clinic/ 3rduspstf/pancreatic/pancrers.pdf.
20. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003;57:23-9.
21. Diehl SJ, Lehmann KJ, Sadick M, Lachmann R, Georgi M. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998;206:373-8.
22. Maringhini A, Ciambra M, Raimondo M, Baccelliere P, Grasso R, Dardanoni G, et al. Clinical presentation and ultrasonography in the diagnosis of pancreatic cancer. Pancreas 1993;8:146-50.
23. Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997;45:387-93.
24. Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann JF. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000;356:190-3.
25. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18) F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-54.
26. Fuhrman GM, Charnsangavej C, Abbruzzese JL, Cleary KR, Martin RG, Fenoglio CJ, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994;167:104-11.
27. Midwinter MJ, Beveridge CJ, Wilsdon JB, Bennett MK, Baudouin CJ, Charnley RM. Correlation between spiral computed tomography, endoscopic ultrasonography and findings at operation in pancreatic and ampullary tumours. Br J Surg 1999;86:189-93.
28. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. 6th ed. New York: Springer, 2002.
29. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
30. Gress FG, Hawes RH, Savides TJ, Ikenberry SO, Cummings O, Kopecky K, et al. Role of EUS in the preoperative staging of pancreatic cancer: a large single-center experience. Gastrointest Endosc 1999;50:786-91.
31. Reddy KR, Levi J, Livingstone A, Jeffers L, Molina E, Kligerman S, et al. Experience with staging laparoscopy in pancreatic malignancy. Gastrointest Endosc 1999;49(4 pt 1):498-503.
32. Steer ML. Exocrine pancreas. In: Townsend CM Jr, ed. Sabiston Textbook of surgery: the biological basis of modern surgical practice. 17th ed. Pennsylvania: Elsevier, 2004:1671.
33. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-37.
34. Seiler CA, Wagner M, Sadowski C, Kulli C, Buchler MW. Randomized prospective trial of pylorus-preserving vs. classic duodenopancreatectomy (Whipple procedure): initial clinical results. J Gastrointest Surg 2000;4:443-52.
35. Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 1996;223:506-11.
36. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer [published correction appears in N Engl J Med 2004;351:726]. N Engl J Med 2004;350:1200-10.
37. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-57.
38. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003;237:74-85.
39. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006-10.
40. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-82.
41. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.
42. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
43. Crown J, Casper ES, Botet J, Murray P, Kelsen DP. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991;9:1682-6.
44. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991;9:2128-33.
45. Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 1988;61:1110-6.
46. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 1981;48:1705-10.
47. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-5.
48. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293-302.
49. Gunaratnam NT, Sarma AV, Norton ID, Wiersema MJ. A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc 2001;54:316-24.
50. Prat F, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998;47:1-7.
51. Yim HB, Jacobson BC, Saltzman JR, Johannes RS, Bounds BC, Lee JH, et al. Clinical outcome of the use of enteral stents for palliation of patients with malignant upper GI obstruction. Gastrointest Endosc 2001;53:329-32.